BioVaxys Technology Corp. Announces Debt Settlement Agreement
Vancouver, BC, April 1, 2025 – BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) has entered into a debt settlement agreement with THECCSGROUP to settle an aggregate of $60,000 in debt by issuing 1,200,000 common shares at a deemed value of $0.05 per share. The Company’s board of directors determined that settling the outstanding debt through share issuance is in the best interest of preserving cash for working capital purposes.
The debt settlement is subject to applicable corporate and regulatory approvals, including acceptance by the Canadian Securities Exchange. All securities issued will be subject to a four-month statutory hold period from the date of issuance.
BioVaxys Technology Corp. is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies based on its DPX™ immune-educating technology platform and HapTenix© ‘neoantigen’ tumor cell construct platform for treating cancers and infectious diseases. The Company’s clinical-stage pipeline includes maveropepimut-S, currently in Phase II development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma and platinum-resistant ovarian cancer, and BVX-0918, a personalized immunotherapeutic vaccine soon to enter Phase I trials in Spain for late-stage ovarian cancer.
This news release contains forward-looking statements within the meaning of applicable securities legislation. These statements are based on assumptions and estimates made by BioVaxys, which are subject to significant business, economic, and competitive uncertainties. Actual results may differ materially from those expressed or implied in the forward-looking statements.
The Canadian Securities Exchange has not reviewed or approved the contents of this press release.
